Clinical Benefit of Niraparib to TKI/mTORi-Resistance Metastatic ccRCC With BAP1-Frame Shift Mutation: Case Report and Literature Review

Saved in:
Bibliographic Details
Published inFrontiers in oncology Vol. 12; p. 927250
Main Authors Lian, Bi-Jun, Zhang, Ke, Fang, Xu-Dong, Li, Feng, Dai, Zhao, Chen, Wei-Ying, Qi, Xiao-Ping
Format Report
LanguageEnglish
Published 01.01.2022
Online AccessGet full text

Cover

More Information
Bibliography:ObjectType-Case Study-2
content type line 59
SourceType-Reports-1
ObjectType-Report-1
ISSN:2234-943X
2234-943X
DOI:10.3389/fonc.2022.927250